RIL Digital Health invests in health tech startup Karkinos Healthcare




Oncology-focussed managed platform Karkinos has received an undisclosed amount of investment from Reliance Digital Health, a statement said on Sunday.


The start-up, backed by Ratan Tata personally and the Tata Group, has other major angel investors that include Venu Srinivasan, Kris Gopalakrishnan, Ronnie Screwvala, Vijay Shekar Sharma and Bhavish Agarwal.





The San Diego, Californai-based Rakuten Medical, the global clinical stage biotechnology firm also holds a minority stake it it.


The Tata Group had recently invested Rs 110 crore into this technology-driven oncology-focussed managed platform that helps in early detection and diagnosis of common cancers. Using a distributed cancer care network, it works with multiple healthcare institutions and professionals to get cancer care closer to the patient’s home by decoupling the delivery from the knowledge systems of care.


The statement said Reliance Industries has invested an undisclosed sum in Karkinos through Reliance Digital Health for a minority stake.


Commenting on the investment, Venkataramanan R, chief executive of Karkinos Healthcare said this investment yet again validates our pioneering model of distributed cancer care and the potential impact it can have in the country.


Though headquartered in Mumbai, it has operations only in Kerala now with services available in four locations in the state- Kothamangalam and Chottanikkara in Ernakulma district of Kerala. and Thodupuzha and Munnar of Idukki district, and is planning to ramp up its operations across the country.


The company launched in July 2020 is also setting up a cancer control centre at the Jawaharlal Nehru Institute of Medical Sciences premises in Imphal, Manipur.


Karkinos means elimination of cancer as ‘kark’ in Hindi means cancer as ‘nos’ means elimination.


Its co-founders and key management team are mostly ex-Tata group personnel such as R Venkataramanan, who was the former managing trustee of Tata Trusts, co-founder Ravi Kant a former vice-chairman and managing director of Tata Motors.


Other cofounders include Dr. Shahvir Nooryezdan who is a dentist and founder of Equinox Medical Technologies; Sundar Raman Dr Moni Abraham K who is the group medical director and the CEO of Karkinos Kerala; Moni Abraham Kuriakose surgical oncologist, Manish Thakkar who is the COO is from Avanti Finance, a fintech company founded by Ratan Tata and Mr. Nandan Nilekani; Sripriya Rao is another COO, Raja Sekhar Kommu is the CTO; Venkataramani Suresh is CBO and Manish Sharma who is also co-founder and the CPO of the company.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *